The current financial score of Integra Lifesciences Holdings Corp is 7.75. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 418.76M, representing a year-over-year increase of 0.76%, while its net profit experienced a year-over-year increase of 100.93%.
The current valuation score of Integra Lifesciences Holdings Corp is 8.97. Its current P/E ratio is -2.35, which is -4674.96% below the recent high of 107.70 and -12717.17% above the recent low of -301.73.
The current earnings forecast score of Integra Lifesciences Holdings Corp is 6.50. The average price target is 19.88, with a high of 27.00 and a low of 14.00.
The current price momentum score of Integra Lifesciences Holdings Corp is 4.06. Currently, the stock price is trading between the resistance level at 16.74 and the support level at 14.29, making it suitable for range-bound swing trading.
The current institutional shareholding score of Integra Lifesciences Holdings Corp is 10.00. The latest institutional shareholding proportion is 106.43%, representing a quarter-over-quarter increase of 10.94%.
The current risk assessment score of Integra Lifesciences Holdings Corp is 5.33. The company's beta value is 1.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.